RECRUITINGOBSERVATIONAL
Multicenter Study for the Validation of an AI-based ECG Platform for Early Cardiac Amyloidosis Diagnosis
Multicenter Study for the Validation of an AI-based ECG Platform for Early Cardiac Amyloidosis Diagnosis (CONCERTO)
About This Trial
CONCERTO is a retrospective, observational, multicentric and single-arm study to perform an external validation of the cloud-based and AI-powered electrocardiogram (ECG) analysis platform, named Willem™, to detect Transthyretin cardiac amyloidosis (ATTR-CA). Thus, this study will assess Willem™ ability to distinguish between truly diagnosed ATTR-CA patients and confirmed non-ATTR-CA patients from ECG data.
Who May Be Eligible (Plain English)
Who May Qualify:
- Subjects ≥ 18 years old
- Subjects with 12-leads ECG records with a 10 seconds minimum length on digital format
Who Should NOT Join This Trial:
- Patients with paced rhythm on the ECG.
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Subjects ≥ 18 years old
* Subjects with 12-leads ECG records with a 10 seconds minimum length on digital format
Exclusion Criteria:
* Patients with paced rhythm on the ECG.
Locations (10)
Northwestern University
Evanston, Illinois, United States
Centre Hospitalier Universitaire de Toulouse
Toulouse, France
Universitätsklinikum Bonn
Bonn, Germany
L'Azienda Ospedaliero-Universitaria di Bologna Policlinico S. Orsola-Malpighi
Bologna, Italy
Careggi University Hospital
Florence, Italy
United Hospitals of Trieste University Hospital
Trieste, Italy
Hospital Universitario Son Llàtzer
Palma de Mallorca, Balearic Islands, Spain
Hospital Universitario Donostia
San Sebastián, Guipúzcoa, Spain
Hospital Universitario Juan Ramón Jiménez
Huelva, Huelva, Spain
Queen Elizabeth University Hospital, Univeisity of Glasgow
Glasgow, United Kingdom